Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Pancreatitis on Mounjaro (tirzepatide for T2D): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label timing / no peak week or onset window is stated; patients are to be observed carefully after starting Mounjaro [1]
  • Label warning / acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists or Mounjaro [1]
  • Trial risk / RR 1.46 (95% CI 0.59 to 3.61) in a 9-trial meta-analysis of 9,871 participants; not statistically significant [2]
  • Real-world signal / a review of observational studies found no clear increase in severe events such as pancreatitis [3]

What the Mounjaro label says about timing

The Mounjaro label lists acute pancreatitis under Warnings and Precautions. Its wording is broader than a simple risk statement: acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or Mounjaro [1].

The only timing instruction is to observe patients carefully after starting Mounjaro for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Mounjaro and initiate appropriate management [1]. The label does not name a peak week or a typical onset window.

What the trial evidence shows

A 2023 systematic review and meta-analysis pooled nine randomized trials with 9,871 participants (6,828 on tirzepatide and 3,043 controls) and found that an increased risk of pancreatitis was not significantly associated with tirzepatide (RR 1.46, 95% CI 0.59 to 3.61; p=0.436) [2]. Controls were basal insulin, dulaglutide or semaglutide once weekly, and placebo [2]. A separate meta-analysis of 21 trials with 99,599 patients, which included tirzepatide among eight GLP-1 receptor agonists, found no difference in pancreatitis between GLP-1 receptor agonist groups and controls [4].

A 2025 review of real-world studies of GLP-1 receptor agonist users found no clear increase in severe events such as pancreatitis [3].

Frequently asked questions

Is there a week-by-week timeline for pancreatitis on Mounjaro?
The Mounjaro label does not give one. It says to observe patients carefully for signs and symptoms of acute pancreatitis after initiation of the drug [1].
How common was pancreatitis in tirzepatide trials?
A 2023 meta-analysis of nine randomized trials with 9,871 participants found no statistically significant increase in pancreatitis with tirzepatide versus controls (RR 1.46, 95% CI 0.59 to 3.61) [2].
What symptoms does the Mounjaro label warn about?
Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].
Does the label mention fatal pancreatitis?
Yes. The label says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or Mounjaro [1].

References

  1. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
  2. Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
  3. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27 Suppl 2(Suppl 2):66-88. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies
  4. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients
Evidence overview for Pancreatitis on Mounjaro (tirzepatide for T2D): Week-by-Week Timeline of What to Expect